

# MARKET REPORT



Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

## Summary

GlobalData's clinical trial report, "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

\*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

\*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

\*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Additional Details

**Publisher** : Global Data

**Reference** : GDHC3492CTIDB

**Number of Pages** : 2060

**Report Format** : PDF

**Publisher Information** :



**GlobalData** »

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

- Table of Contents
- Table of Contents
- 2List of Tables
- 5List of Figures
- 6Report Guidance
- 7Clinical Trials by Region
- 8Clinical Trials and Average Enrollment by Country
- 9Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- 11Top Five Countries Contributing to Clinical Trials in Europe
- 12Top Countries Contributing to Clinical Trials in North America
- 13Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- 14Top Five Countries Contributing to Clinical Trials in Central and South America
- 15Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials
- 16Clinical Trials by Phase in G7 Countries
- 17Clinical Trials in G7 Countries by Trial Status
- 18Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials
- 19Clinical Trials by Phase in E7 Countries
- 20Clinical Trials in E7 Countries by Trial Status
- 21Clinical Trials by Phase
- 22In Progress Trials by Phase
- 23Clinical Trials by Trial Status
- 24Clinical Trials by End Point Status
- 25Subjects Recruited Over a Period of Time
- 26Clinical Trials by Sponsor Type
- 27Prominent Sponsors
- 28Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials
- 29Prominent Drugs
- 31Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- 32Jun 14, 2016: Celator Pharmaceuticals Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia
- 32Jun 11, 2016: Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
- 33Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1425 at 21st Congress of the European Hematology Association
- 34Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association
- 34Jun 09, 2016: AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine
- Venetoclax
- 35Jun 08, 2016: Actinium to Present at BIO International Convention to Provide Update on Actimab-A Program
- 36Jun 07, 2016: BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
- 36Jun 06, 2016: Celator Pharmaceuticals Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival
- 37Jun 06, 2016: Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting
- 38Jun 06, 2016: Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016
- 39Jun 06, 2016: SELLAS Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia and Malignant Pleural Mesothelioma, as Presented at the 2016 ASCO Annual Meeting
- 39Jun 06, 2016: Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting
- 41Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers
- 41Jun 01, 2016: Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia and Provides Guidance on Plans for Phase 2 Clinical Trial
- 42May 31, 2016: Mundipharma EDO Announces First-in-human Clinical Trial of its Lead Compound, EDO-S101
- 43May 25, 2016: Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
- 44May 25, 2016: GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine
- 45May 24, 2016: SELLAS Life Sciences Announces Upcoming Presentation of Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting
- 45May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting
- 46May 19, 2016: Celator Pharmaceuticals Announces Upcoming Phase 3 Data Presentations at American Society of Clinical Oncology and European Hematology Association
- 47May 19, 2016: Syros Pharmaceuticals to Present on SY-1425 at 21st Congress of the European Hematology Association
- 47May 18, 2016: AbbVie To Present Data on Venclexta (venetoclax) at ASCO 2016
- 48May 18, 2016: Actinium Announces Webinar to Discuss Results of the Actimab-A Phase 1 Trial and Key Findings From the HuM195-Alpha Program
- 48May 16, 2016: Fate Therapeutics Announces Preclinical

Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy 49  
May 11, 2016: Clinical data of Medigene dendritic cell vaccines in AML presented at CIMT conference 50  
May 11, 2016: Clinical data of Medigene's dendritic cell vaccines in AML presented at CIMT conference 50  
May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting 51  
Apr 25, 2016: Celator Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS Compared to Standard Treatment for Acute Myeloid Leukemia (AML) 51  
Apr 25, 2016: GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference 52  
Apr 25, 2016: Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B 52  
Apr 21, 2016: Celator Pharmaceuticals to Present Phase 3 Data at 2016 American Society of Clinical Oncology Annual Meeting 53  
Apr 20, 2016: Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia 53  
Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016 54  
Apr 18, 2016: Calithera Biosciences Announces Preclinical Presentation of CB-839 at the American Association for Cancer Research Annual Meeting 2016 54  
Apr 18, 2016: Celator Pharmaceuticals Announces Data for VYXEOS in FLT3-ITD Mutated AML Cells Derived from Patients with Newly Diagnosed AML to be Presented at the American Association for Cancer Research Annual Meeting 55  
Apr 18, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Cancer Activity of SY-1425 in Preclinical Models of Acute Myeloid Leukemia 55  
Apr 18, 2016: Celator Pharmaceuticals Announces Positive Data for VYXEOS in FLT3-ITD Mutated Acute Myeloid Leukemia Cells Derived from Patients with Newly Diagnosed AML 56  
Apr 18, 2016: ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMG779 for Acute Myeloid Leukemia 56  
Apr 12, 2016: UPDATE - Actinium Announces Selection of Zevacor Pharma for Clinical Production and Supply of Iomab-B for Pivotal Phase 3 SIERRA Trial 57  
Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 57  
Apr 01, 2016: SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig) 58  
Clinical Trial Profile Snapshots 60  
Appendix 2057  
Abbreviations 2057  
Definitions 2057  
Research Methodology 2058  
Secondary Research 2058  
About GlobalData 2059  
Contact Us 2059  
Disclaimer 2059  
Source 2060

# List Of Tables in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

## List of Tables

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2016\* 8

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016\* 9

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016\* 10

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016\* 11

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016\* 12

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2016\* 13

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016\* 14

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016\* 15

Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016\* 16

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016\* 17

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016\* 18

Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016\* 19

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016\* 20

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016\* 21

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2016\* 22

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016\* 23

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016\* 24

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016\* 25

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016\* 27

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016\* 28

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016\* 30

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016\* 31



# List Of Figures, Charts and Diagrams in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

## List of Figures

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2016\* 8

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016\* 9

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016\* 10

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016\* 11

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016\* 12

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016\* 13

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016\* 14

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016\* 15

Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016\* 16

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016\* 17

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016\* 18

Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016\* 19

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016\* 20

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016\* 21

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016\* 22

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016\* 23

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016\* 24

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016\* 25

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016\* 27

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016\* 28

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016\* 29

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016\* 31

GlobalData Methodology 2058

# How to Buy...

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27033>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.